According to the World Health Organization, liver cancer is the second most common cause of cancer death, so the ability to diagnose it accurately and early is imperative. For liver cancer, 85 to 90 percent of liver cancer cases are hepatocellular carcinoma (HCC).  As of now, six-month interval ultrasounds are used to survey patients at risk for developing HCC. Although they may be taken regularly, the ultrasound accuracy for detecting early HCC is around approximately 60 percent.

A possible solution to a more accurate HCC diagnosis is biomarker detection. Previous research has shown that finding specific biomarkers linked to HCC could advance early diagnosis.

We currently have a study for those who are either at risk of developing HCC or have been diagnosed.  If you believe you’re included into one of these two groups and would like to see if you qualify for this study, please contact our research team. You can call our ARC Clinical Research team at 512-225-5931, or fill out our Clinical Research Interest form online.